Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.

ABSTRACT:

Objective

To ascertain the mobilization from the bone marrow and the functional relevance of the increased number of circulating hematopoietic stem and progenitor cells (HSPC) induced by the anti-α-4 integrin antibody natalizumab in patients with multiple sclerosis (MS).

Methods

We evaluated CD45(low)CD34+ HSPC frequency by flow cytometry in blood from 45 natalizumab-treated patients (12 of whom were prospectively followed during the first year of treatment as part of a pilot cohort and 16 prospectively followed for validation), 10 untreated patients with MS, and 24 healthy donors. In the natalizumab-treated group, we also assessed sorted HSPC cell cycle status, T- and B-lymphocyte subpopulation frequencies (n = 29), and HSPC differentiation potential (n = 10).

Results

SUBMITTER: Mattoscio M 

PROVIDER: S-EPMC4395887 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature